ATP III GP, Ltd. 4
4 · Stoke Therapeutics, Inc. · Filed Jun 21, 2019
Insider Transaction Report
Form 4
Apple Tree Partners IV, L.P.
10% Owner
Transactions
- Conversion
Common Stock
2019-06-21+4,980,168→ 4,980,168 total - Conversion
Common Stock
2019-06-21+2,799,910→ 15,397,824 total - Conversion
Series A Convertible Preferred Stock
2019-06-21−4,980,168→ 0 total→ Common Stock (4,980,168 underlying) - Conversion
Common Stock
2019-06-21+7,617,746→ 12,597,914 total - Purchase
Common Stock
2019-06-21$18.00/sh+1,388,889$25,000,002→ 16,786,713 total - Conversion
Series A-2 Convertible Preferred Stock
2019-06-21−7,617,746→ 0 total→ Common Stock (7,617,746 underlying) - Conversion
Series B Convertible Preferred Stock
2019-06-21−2,799,910→ 0 total→ Common Stock (2,799,910 underlying)
Footnotes (2)
- [F1]The shares of Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, Series B Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering on June 21, 2019.
- [F2]Apple Tree Partners IV, L.P. ("ATP IV"). ATP III GP, Ltd. ("ATP III"), is the sole general partner of ATP IV. Seth Harrison, a director of Issuer, is the sole director of ATP III and may be deemed to have sole voting and dispositive power over the shares held by ATP IV. Dr. Harrison disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.